Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Preventive Medicine Precision Panel > ACMG Actionable Diseases Precision Panel

ACMG Actionable Diseases Precision Panel

The American College of Medical Genetics and Genomics (ACMG) Actionable Diseases Gene Panel shows a comprehensive selection of genes by ACMG.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • The American College of Medical Genetics and Genomics (ACMG) Actionable Diseases Gene Panel shows a comprehensive selection of genes by ACMG. Mutations in these genes lead to disorders that have been scientifically proven to be actionable, meaning that early intervention improves prognosis, life expectancy, quality of life and overall well-being. Early identification before the onset of manifestations allows the prevention of symptoms thus initiating prompt multidisciplinary treatment. The main goal is to report the known or expected pathogenic variants in these genes while performing exome and genome sequencing, even if those are unrelated to the primary medical reason for testing. 

  • The Igenomix ACMG Actionable Disorders Precision Panel can be used to identify those genes and perform a screening, whether the patient shows symptoms or not, to locate mutations and start an early treatment. 

Indication

The Igenomix ACMG Actionable Disorders Precision Panel is indicated as a screening and diagnostic test in those cases where there are: 

  • Family history of cancer or cardiomyopathy    
  • Multiple relatives on the same side of the family with any form of cancer or cardiomyopathy. 
  • Asymptomatic patients who wish to check the chance of developing any of the reported diseases.  

Clinical Utility

The clinical utility of this panel is:  

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of multidisciplinary treatment including lifestyle modifications, early surveillance from malignancy, regular follow up with a specialist, and medical or surgical care if needed.  
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Family planning for adequate reproductive decisions, using available assisted reproduction technology. 

Genes & Diseases

Methodology

References

See scientific referrals

Kalia, S., Adelman, K., Bale, S. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 19, 249–255 (2017). 

Green, R., Berg, J., Grody, W. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 15, 565–574 (2013) 

ACMG Board of Directors. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med 17, 68–69 (2015) 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information